Evidence map›Paper›PMID 34691287›Full record

ArticleDisease markers2021

Study on the Killing Effect of

Zaiwang Chen, Yujuan Zhao, Xiangqi Li, Keqiang Wang

RetractedOpen access · hybridAbstract readRetracted Publication
PubMed Full text at PMC Publisher
In one paragraph

Article in Disease markers, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It has been retracted, and should not be counted. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.3field-weighted citation impact, top 45% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 4 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. CD3Computational and mathematical methods in medicine · 2021
    Article
4 · The record

Corrections and comments

  • Retraction · 2023-07-12Concerns/Issues about Data · Concerns/Issues about Results and/or Conclusions · Concerns/Issues about Referencing/Attributions · Concerns/Issues about Peer Review · Investigation by Journal/Publisher · Investigation by Third Party · Computer-Aided Content or Computer-Generated Content · Unreliable Results and/or Conclusions ·
  • Retracted
5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Zaiwang ChenDepartment of Laboratory Medicine, Second Affiliated Hospital of Shandong First Medical University, Tai'an, Shandong Province, China 271000.
Yujuan ZhaoDepartment of Emergency Medicine, Yingsheng District, Tai'an Central Hospital, Tai'an City, Shandong Province, China 271000.
Xiangqi LiBreast Surgery, Second Affiliated Hospital of Shandong First Medical University, Tai'an, Shandong Province, China 271000.ORCID https://orcid.org/0000-0002-7106-9473
Keqiang WangDepartment of Laboratory Medicine, Second Affiliated Hospital of Shandong First Medical University, Tai'an, Shandong Province, China 271000.ORCID https://orcid.org/0000-0002-0992-6016
Affiliated Hospital of Taishan Medical University · CNTaian City Central Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveTo investigate the killing effect of rukangyin (RKY) activated

methodsThus, study isolates peripheral blood mononuclear cells (PBMC) and uses CCK8 to select the optimal concentration of Rukang drink, ZOL (zoledronic acid), and PHA (phytoagglutinin) to activate

resultsThe optimal concentrations of RKY, ZOL, and PHA to activate

conclusionRukangyin can increase the lethality of

Indexed as

Breast NeoplasmsCell Line, TumorCell SurvivalDrugs, Chinese HerbalFemaleFlow CytometryHumansImmunotherapyLeukocytes, MononuclearLymphocyte ActivationT-Lymphocyte SubsetsZoledronic AcidDrugs, Chinese HerbalZoledronic Acid

Identifiers

PMID34691287
PMCPMC8536438
OpenAlexW3205519468

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.